title: The inferiority of G-PB to rhG-CSF-mobilized blood and marrow grafts as a stem cell source in patients with high-risk acute leukemia who underwent unmanipulated HLA-mismatched/haploidentical transplantation: a comparative analysis.
abstract: The purpose of this study was to investigate the efficacy and feasibility of unmanipulated haploidentical PBSCT for the treatment of acute leukemia (AL). This study compares the clinical outcomes of high-risk AL patients who received PBSCs harvested from family members sharing at least one common haplotype to outcomes of high-risk AL patients who received a mixture of G-CSF-primed BM (G-BM) and peripheral blood (G-PB) harvests. The results show that PBSCT achieved inferior cumulative myeloid engraftment at 30 days after transplant (89.9 + or - 10.1% vs 100%; P=0.04), with lower cumulative incidence of grade II-IV acute GVHD (aGVHD) (37.1 + or - 16.5% vs 63.2+/-6%; P=0.058) compared with G-BM/G-PB transplant. However, both transplant protocols had similar rates of 2-year relapse (29.6 + or - 17.1% vs 34.0 + or - 5.7%; P=0.954), and PBSCT produced a higher incidence of 2-year non-leukemic mortality (62.5 + or - 14.8% vs 35.1 + or - 5.1%; P=0.014), as well as lower rates of overall (26.8 + or - 12.3% vs 43.2 + or - 5.0%; P=0.052) and disease-free survival (26.8 + or - 12.3% vs 42.4 + or - 5.0%; P=0.071) compared with G-BM/G-PB transplant. These results suggest that haploidentical HSCT is an option for patients with AL who urgently need a graft and do not have matched sibling donors. PBSCT is potentially inferior to G-BM/G-PB transplant, and improvements should be made before PBSCT becomes a routine in unmanipulated mismatched/haploidentical transplant settings.
authors.affiliation: Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, PR China.
authors.forename: L-P
authors.initials: LP
authors.lastname: Xu
authors.forename: K-Y
authors.initials: KY
authors.lastname: Liu
authors.forename: D-H
authors.initials: DH
authors.lastname: Liu
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: W
authors.initials: W
authors.lastname: Han
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chen
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: X-J
authors.initials: XJ
authors.lastname: Huang
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000379:methods*; D002648:Child; D005190:Family; D005260:Female; D006085:Graft Survival; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006239:Haplotypes; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012038:Regeneration; D015996:Survival Rate; D014181:Transplantation Immunology / Q000276:immunology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D016179:Granulocyte Colony-Stimulating Factor